INVESTOR RELATIONS

  • December Investor Presentation19/12/2018View
  • Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
  • HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
  • Becoming a substantial holder – Tal Slonim11/12/2018View
  • Becoming a substantial holder – David Groberman11/12/2018View
  • Initial Director’s Interest Notice – Tal Slonim11/12/2018View
  • Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
  • Initial Director’s Interest Notice – Doron Birger11/12/2018View
  • Initial Director’s Interest Notice – David Hinton11/12/2018View
  • Initial Director’s Interest Notice – David Groberman11/12/2018View
  • Statement of Confirmations10/12/2018View
  • Updated Statement of Commitments10/12/2018View
  • Voluntary Escrow10/12/2018View
  • Restricted Securities10/12/2018View
  • Updated Pro Forma Statement of Financial Position10/12/2018View
  • Capital Structure10/12/2018View
  • Securities Trading Policy10/12/2018View
  • Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
  • Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
  • Supplementary Prospectus10/12/2018View
  • Prospectus10/12/2018View
  • Constitution10/12/2018View
  • Appendix 1A and Information Form and Checklist10/12/2018View
  • Top 20 Holders10/12/2018View
  • Distribution Schedule10/12/2018View
  • ASX Notice – Admission to Official List10/12/2018View